Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hip implant study aims to reduce dislocation risk in cancer patients

NCT ID NCT05461313

Disease control Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two types of hip implants used in total hip replacement for people with metastatic bone disease (cancer that has spread to the hip bone). The goal is to see if a newer implant design (dual mobility) is as good as a standard one (constrained liner) at preventing the hip from popping out of place after surgery. About 146 adults with cancer in the hip bone will take part, and their dislocation rates will be checked at 3 and 6 months after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 146 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with metastatic bone disease of the hip defined as bone lesions in the proximal femur because of secondary malignant growth of a primary cancer located elsewhere or bone lesions in the proximal femur due to hematological malignancies * Determined eligible for total hip arthroplasty for metastatic bone disease of the hip and is planned to undergo surgery at the study site * Provides informed consent prior to initiation of any study-specific activities/procedures Exclusion Criteria: * Previous osteosynthesis or endoprosthetic surgery of the ipsilateral hip * Pelvic reconstruction of the ipsilateral hip * Total femoral replacement of the ipsilateral femur * It is not surgically viable to insert an acetabular cup and/or a femoral stem * Subject is currently or has previously been enrolled in this study * Subject is incapable of understanding the patient information or unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic cancer to the hip are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone disorder metastatic carcinoma in the bone

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic cancer to the hip

Contacts and locations

Locations

  • Department of Orthopedic Surgery, Rigshospitalet

    Copenhagen, 2100, Denmark